TuHURA Biosciences to Present at Canaccord Genuity Conference

TuHURA Biosciences, Inc. announced on July 22, 2026, that its President and CEO, James A. Bianco, M.D., will present at the Canaccord Genuity's 46th Annual Growth Conference in Boston, MA. The presentation is scheduled for August 12, 2026.

The conference provides a platform for TuHURA to discuss its progress in developing therapies aimed at overcoming primary and acquired resistance to cancer immunotherapy. This resistance is a major obstacle that limits the effectiveness of current treatments for a significant number of cancer patients.

TuHURA's focus is on enhancing the immune system's response to cancer. Their lead therapeutic candidate, IFx-2.0, is designed to combat resistance to checkpoint inhibitors and is currently undergoing a Phase 3 registration trial. The company is also advancing other potential treatments, including a VISTA inhibitor and antibody-drug conjugates targeting immunosuppressive cells.

An archived webcast of the presentation will be accessible on TuHURA's investor relations website. Additional information, including a recent interview with Dr. Bianco, is also available online.

TuHURA Biosciences is a clinical-stage immuno-oncology company dedicated to creating novel therapeutics to address resistance in cancer immunotherapy, aiming to improve outcomes for patients whose cancers do not respond to existing treatments.